Published in J Exp Med on April 21, 2008
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
The complement system. Cell Tissue Res (2010) 1.86
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization. PLoS One (2011) 1.57
Neuroimmunological blood brain barrier opening in experimental cerebral malaria. PLoS Pathog (2012) 1.35
Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. J Infect Dis (2011) 1.16
Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem (2010) 1.16
C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS One (2009) 1.16
A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria. PLoS One (2010) 1.10
Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS One (2011) 1.03
Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol (2009) 1.02
MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a via the Akt signaling pathway. FASEB J (2011) 1.01
Host resistance to malaria: using mouse models to explore the host response. Mamm Genome (2010) 0.98
Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier. PLoS Pathog (2014) 0.97
Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria. J Immunol (2011) 0.97
Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria. Infect Immun (2013) 0.93
The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem (2012) 0.92
Complement factors C1q, C3 and C5 in brain and serum of mice with cerebral malaria. Malar J (2008) 0.89
Experimental Malaria in Pregnancy Induces Neurocognitive Injury in Uninfected Offspring via a C5a-C5a Receptor Dependent Pathway. PLoS Pathog (2015) 0.84
Deletion of carboxypeptidase N delays onset of experimental cerebral malaria. Parasite Immunol (2012) 0.83
An N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malaria. PLoS One (2012) 0.83
Complement C5-deficient mice are protected from seizures in experimental cerebral malaria. Epilepsia (2014) 0.82
CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model. PLoS One (2013) 0.81
Activation of endogenous anti-inflammatory mediator cyclic AMP attenuates acute pyelonephritis in mice induced by uropathogenic Escherichia coli. Am J Pathol (2014) 0.80
Deletion of the complement phagocytic receptors CR3 and CR4 does not alter susceptibility to experimental cerebral malaria. Parasite Immunol (2012) 0.78
A novel role for the fifth component of complement (C5) in cardiac physiology. PLoS One (2011) 0.77
Increased survival in B-cell-deficient mice during experimental cerebral malaria suggests a role for circulating immune complexes. MBio (2014) 0.76
miR-155 Modifies Inflammation, Endothelial Activation and Blood-Brain Barrier Dysfunction in Cerebral Malaria. Mol Med (2017) 0.76
Pathogenesis of malaria revisited. Med Microbiol Immunol (2012) 0.75
The impact of genetic susceptibility to systemic lupus erythematosus on placental malaria in mice. PLoS One (2013) 0.75
Functions of Antibodies. Microbiol Spectr (2014) 0.75
The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis. Kidney Int (2016) 0.75
C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure. World J Gastroenterol (2016) 0.75
A Plasmodium yoelii HECT-like E3 ubiquitin ligase regulates parasite growth and virulence. Nat Commun (2017) 0.75
Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol (2000) 128.08
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (2005) 12.98
Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med (2004) 7.42
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Role of C5a in inflammatory responses. Annu Rev Immunol (2005) 4.38
Innate immunity to malaria. Nat Rev Immunol (2004) 4.19
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
The dark side of C5a in sepsis. Nat Rev Immunol (2004) 2.46
Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature (2002) 2.31
Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol (1998) 2.05
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev (2001) 1.91
Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med (2002) 1.86
Genomic DNA functions as a universal external standard in quantitative real-time PCR. Nucleic Acids Res (2006) 1.85
Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect (2002) 1.81
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology (1992) 1.78
Profiles of cytokine production in relation with susceptibility to cerebral malaria. J Immunol (1993) 1.77
A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol (2007) 1.67
Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med (1998) 1.57
von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol (2006) 1.55
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol (1989) 1.44
Recombinant congenic strains derived from A/J and C57BL/6J: a tool for genetic dissection of complex traits. Genomics (2001) 1.42
Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J (2003) 1.42
Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. J Infect Dis (2003) 1.41
Cytokine profile suggesting that murine cerebral malaria is an encephalitis. Infect Immun (1997) 1.36
Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J (2001) 1.35
Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology (2001) 1.35
C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol (2004) 1.34
Early cytokine production is associated with protection from murine cerebral malaria. Infect Immun (2005) 1.32
Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci (2003) 1.29
Mouse loci for malaria-induced mortality and the control of parasitaemia. Nat Genet (1997) 1.29
Genetic control of blood parasitaemia in mouse malaria maps to chromosome 8. Nat Genet (1997) 1.22
Identification of a new malaria susceptibility locus (Char4) in recombinant congenic strains of mice. Proc Natl Acad Sci U S A (2001) 1.21
Simultaneous host and parasite expression profiling identifies tissue-specific transcriptional programs associated with susceptibility or resistance to experimental cerebral malaria. BMC Genomics (2006) 1.20
Disruption of CD36 impairs cytokine response to Plasmodium falciparum glycosylphosphatidylinositol and confers susceptibility to severe and fatal malaria in vivo. J Immunol (2007) 1.18
Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol (2001) 1.17
Temporal expression of an H2-linked locus in host response to mouse malaria. Immunogenetics (1999) 1.15
Gene-expression profiling discriminates between cerebral malaria (CM)-susceptible mice and CM-resistant mice. J Infect Dis (2005) 1.15
Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis (2006) 1.13
Conventional and experimental treatment of cerebral malaria. Int J Parasitol (2006) 1.12
Role of cytokines and adhesion molecules in malaria immunopathology. Stem Cells (1993) 1.09
The natural killer complex regulates severe malarial pathogenesis and influences acquired immune responses to Plasmodium berghei ANKA. Infect Immun (2005) 1.07
Identification of two cerebral malaria resistance loci using an inbred wild-derived mouse strain. Proc Natl Acad Sci U S A (2002) 1.03
Not much progress in treatment of cerebral malaria. Lancet (1998) 0.98
Mechanisms of enhanced lung injury during sepsis. Am J Pathol (1999) 0.97
Disruption of JNK2 decreases the cytokine response to Plasmodium falciparum glycosylphosphatidylinositol in vitro and confers protection in a cerebral malaria model. J Immunol (2006) 0.96
Evidence for multiple pathologic and protective mechanisms of murine cerebral malaria. Infect Immun (1998) 0.96
Interferon-gamma synergises with tumour necrosis factor and lymphotoxin-alpha to enhance the mRNA and protein expression of adhesion molecules in mouse brain endothelial cells. Cytokine (2007) 0.96
Complement activation in severe Plasmodium falciparum malaria. Clin Immunol Immunopathol (1997) 0.93
Anaphylatoxin C5a actions in rat liver: synergistic enhancement by C5a of lipopolysaccharide-dependent alpha(2)-macroglobulin gene expression in hepatocytes via IL-6 release from Kupffer cells. J Immunol (2001) 0.93
The priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway. Shock (2007) 0.92
Complement activation in experimental human malaria infection. Trans R Soc Trop Med Hyg (2007) 0.91
Smoke and C5a induce airway epithelial intercellular adhesion molecule-1 and cell adhesion. Am J Respir Cell Mol Biol (2003) 0.91
Detection of a new cerebral malaria susceptibility locus, using CBA mice. Immunogenetics (2004) 0.91
Genetic control of parasite clearance leads to resistance to Plasmodium berghei ANKA infection and confers immunity. Genes Immun (2005) 0.89
Association of a determinant on mouse chromosome 18 with experimental severe Plasmodium berghei malaria. Infect Immun (2002) 0.88
Anti-complement strategies in experimental sepsis. Scand J Infect Dis (2003) 0.80
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc (2009) 6.71
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Role of C5a in inflammatory responses. Annu Rev Immunol (2005) 4.38
The enigma of sepsis. J Clin Invest (2003) 4.32
Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol (2004) 4.17
Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity (2010) 3.96
The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A (2005) 3.84
Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med (2010) 3.83
Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis (2006) 3.69
Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med (2007) 3.64
Mutations in VANGL1 associated with neural-tube defects. N Engl J Med (2007) 3.58
Illness after international travel. N Engl J Med (2002) 3.56
Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis (2007) 3.53
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med (2011) 3.29
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J Infect Dis (2002) 3.13
The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol (2006) 3.11
Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila. Nat Genet (2002) 2.83
Evaluation of the Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am J Trop Med Hyg (2003) 2.75
Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2009) 2.66
Adverse functions of IL-17A in experimental sepsis. FASEB J (2008) 2.60
Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med (2011) 2.59
Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature (2007) 2.56
Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg (2002) 2.55
Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Exp Hematol (2003) 2.25
The phagocytes: neutrophils and monocytes. Blood (2008) 2.25
Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol (2006) 2.18
Malaria. CMAJ (2004) 2.13
Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg (2003) 2.12
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ (2004) 2.11
Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J Immunol (2010) 2.09
Devices for rapid diagnosis of Malaria: evaluation of prototype assays that detect Plasmodium falciparum histidine-rich protein 2 and a Plasmodium vivax-specific antigen. J Clin Microbiol (2003) 2.08
Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science (2012) 2.06
Modulation of lipopolysaccharide-induced gene transcription and promotion of lung injury by mechanical ventilation. J Immunol (2005) 2.05
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet (2003) 1.98
Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study*. Crit Care Med (2012) 1.97
Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One (2009) 1.93
Evaluation of the RealArt Malaria LC real-time PCR assay for malaria diagnosis. J Clin Microbiol (2004) 1.91
Genetic interaction between members of the Vangl family causes neural tube defects in mice. Proc Natl Acad Sci U S A (2008) 1.90
Independent mutations in mouse Vangl2 that cause neural tube defects in looptail mice impair interaction with members of the Dishevelled family. J Biol Chem (2004) 1.90
The Nod-like receptor family member Naip5/Birc1e restricts Legionella pneumophila growth independently of caspase-1 activation. J Immunol (2007) 1.89
Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion (2002) 1.89
The complement system. Cell Tissue Res (2010) 1.86
Advances in malaria diagnosis. Expert Rev Anti Infect Ther (2007) 1.84
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA (2003) 1.81
Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis (2004) 1.80
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Real-time polymerase chain reaction assay for the rapid detection and characterization of chloroquine-resistant Plasmodium falciparum malaria in returned travelers. Clin Infect Dis (2006) 1.79
The mouse Gene Expression Database (GXD): 2014 update. Nucleic Acids Res (2013) 1.78
A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med (2005) 1.74
NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol (2008) 1.73
Furuncular myiasis: a simple and rapid method for extraction of intact Dermatobia hominis larvae. Clin Infect Dis (2002) 1.73
Molecular diagnostic and surveillance tools for global malaria control. Travel Med Infect Dis (2007) 1.73
Generation of C5a by phagocytic cells. Am J Pathol (2002) 1.72
Pyruvate kinase deficiency and malaria. N Engl J Med (2008) 1.72
Role of oxidants in lung injury during sepsis. Antioxid Redox Signal (2007) 1.71
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerg Infect Dis (2008) 1.64
Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane. Blood (2003) 1.63
Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Invest (2006) 1.60
Irf8-regulated genomic responses drive pathological inflammation during cerebral malaria. PLoS Pathog (2013) 1.59
Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J (2009) 1.59
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol (2013) 1.57
Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell Host Microbe (2013) 1.57
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis (2007) 1.56
Proteomic analysis of Salmonella enterica serovar typhimurium isolated from RAW 264.7 macrophages: identification of a novel protein that contributes to the replication of serovar typhimurium inside macrophages. J Biol Chem (2006) 1.55
Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS One (2011) 1.55